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Background: In the last few decades, there has been a growing interest in anxiety disorders (AnxD) in the
perinatal period. Although AnxD are diagnosed in 4–39% of pregnant women and in up to 16% of women
after delivery, evidence on their clinical management is limited.
Methods: A systematic review was conducted on pharmacological and non-pharmacological treatment of
AnxD in the perinatal period. Relevant papers published from January 1st 2015 were identiﬁed searching
the electronic databases MEDLINE, Embase, PsycINFO and the Cochrane Library.
Results: 18 articles met inclusion criteria. Selected studies supported the use of cognitive-behavioural
therapy (CBT) for obsessive–compulsive disorder (OCD), panic disorder (PD) and speciﬁc phobia both in
pregnancy and postpartum. Selective serotonin reuptake inhibitors (SSRIs) led to signiﬁcant OCD and PD
improvement both in pregnancy and postpartumwith no side effects for the babies. In the largest clinical
sample to date, 65% of postpartum patients who entered the open-label trial of ﬂuvoxamine (up to
300 mg/day) experienced a 30% or greater decrease in the total score of the Yale–Brown Obsessive–
Compulsive Scale (Y-BOCS). During pregnancy, SSRIs and tricyclic antidepressants (TCAs) led to remission
of panic symptoms and healthy outcomes for the babies.
Limitations: Study design, mostly case reports, and enrolment of subjects mainly from outpatient spe-
cialty units might have limited community-wide generalisability.
Conclusions: Keeping in mind the scantiness and heterogeneity of the available literature, the best in-
terpretation of the available evidence appears to be that CBT should be the ﬁrst treatment offered to
pregnant and breastfeeding women with AnxD. However SSRIs can represent a ﬁrst line treatment
strategy, and not exclusively in cases where AnxD is refractory to CBT.
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Even though pregnancy is a period of emotional well-being for
most women, one fourth of pregnant women are affected by a
mental disorder, with one-twelfth experiencing one of these dis-
orders for the ﬁrst time (Vesga-Lopez et al., 2008). Over the last
few decades, more attention has been focused on anxiety dis-
orders (AnxD), which were more extensively investigated in an-
tenatal period (Goodman and Chenausky, 2014) than in post-
partum.
AnxD are diagnosed in 4–39% of pregnant women (Goodman
and Chenausky, 2014) and prevalence rates are even higher if co-
morbid disorders are also considered (Marchesi et al., 2014).
Although prenatal AnxD increase the risk of post-partum de-
pression (Goodman and Chenausky, 2014), their effects on ob-
stetric outcomes are debated. Regarding neonatal/infant outcomes,
a low brain-derived neurotrophic factor (BDNF) level in the blood
cord; no heart rate response to the mother anxiety; increase cor-
tisol reactivity to stress (not replicated in other two studies) and
early attention dysfunction, were found in infants of mothers with
prenatal AnxD (Goodman and Chenausky, 2014).
With regard to the post-partum period, AnxD are diagnosed in
16% of women (Vesga-Lopez et al., 2008; Austin et al., 2010;
Wenzel et al., 2005; Reck et al., 2008) and up to 50% if comorbid
major depression is also taken into account (Austin et al., 2010;
Wenzel et al., 2005).
Untreated AnxD increase the risk of postpartum depression
(Prenoveau et al., 2013) and have been associated with maternal
low self-conﬁdence (Zietlow et al., 2014); early complications in
the offspring (e.g. behavioural inhibition, mother–infant interac-
tion problems, insecure attachment), and later adverse child de-
velopment (Glasheen et al., 2010).
Recent reviews have mostly focused on prevalence rates and
clinical presentation of AnxD in pregnant and postpartum women
(Goodman and Chenausky, 2014; Ross and McLean, 2006). This is
the ﬁrst systematic review on pharmacological and non-pharma-
cological treatment approaches of perinatal AnxD.1.1. Aim of the study
We systematically reviewed the available literature on the
treatment of perinatal AnxD and we provide recommendations for
clinical management and future research.2. Materials and methods
We conducted this review according to the methods re-
commended by the Cochrane Collaboration and documented the
process and results in accordance with the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines (Liberati et al., 2009; Higgins and Green, 2011).
2.1. Information sources and search strategy
Studies were identiﬁed by searching the electronic databases
MEDLINE, Embase, PsycINFO, and the Cochrane Library. We com-
bined the search strategy of free text terms and exploded MESH
headings for the topic of pharmacological and non-pharmacolo-
gical treatment of AnxD in perinatal period combined as follow-
ing: (((((pregnan*) OR perinatal) OR breastfeeding[MeSH Terms]))
AND ((anxiety[MeSH Terms]) OR anxiety disorder[MeSH Terms]))
AND (((treatment) OR therap*) OR pharmacotherap*). The strategy
was ﬁrst developed in MEDLINE and then adapted for use in the
other databases (Appendix A). Studies published in English
through January 1st, 2015 were included. In addition, further
studies were retrieved from the reference listings of relevant ar-
ticles and consultation with experts in the ﬁeld.
2.2. Inclusion criteria
2.2.1. Study population and study design
We considered studies that included women with AnxD during
perinatal period. All anxiety disorders were considered if diag-
nostic criteria used were speciﬁed. Studies enroling women with
OCD were also considered, even though OCD was moved out from
AnxD in the DSM5. However, we chose to include OCD in the re-
view because the sequential order of the DSM5 chapters on AnxD
and OCD and related disorders, reﬂects “the close relationship”
among them (American Psychiatric Association, 2013). Further, the
ﬁrst-choice treatment of OCD is similar to those of AnxD and
therefore the clinical management of OCD during the perinatal
period is largely overlapping to that of AnxD.
Participants younger than 18 years of age were also considered.
Among hospital-based studies, inpatients, day-hospital and
outpatient subjects were included while emergency care records
were excluded as being considered non-representative. All ex-
perimental and observational study designs were included. Nar-
rative and systematic reviews, letters to the editor and book
chapters were excluded.
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Either pharmacologic, psychotherapeutic and other alternative
approaches were considered.
2.2.3. Study selection and data extraction
Identiﬁed studies were independently reviewed for eligibility
by two authors (AA, PO) in a two-step based process; a ﬁrst
screening was performed based on title and abstract while full
texts were retrieved for the second screening. At both stages dis-
agreements by reviewers were resolved by consensus. Data were
extracted by two authors (AA, PO) and supervised by a third au-
thor (CM) using an ad-hoc developed data extraction spreadsheet.
The data extraction spreadsheet was piloted on 10 randomly se-
lected papers and modiﬁed accordingly.
2.2.4. Quality assessment
The same authors who performed data extraction (AA, PO)
independently assessed the quality of selected studies using the
checklist developed by Downs and Black both for randomized and
non-randomized studies (Downs and Black, 1998). Disagreements
by reviewers were resolved by consensus. Table 1 shows the
quality assessment total score assigned to each study.3. Results
One thousand two hundred potential studies were identiﬁed
from searching the selected databases and listing references ofTable 1
Studies that met inclusion criteria for systematic review.
References Study design Country Study population
Pregnancy
Obsessive–compulsive disorder
Chelmow and Halﬁn (1997) Case report USA 1 pregnant woman (age
Kalra et al. (2005) Case report India 1 pregnant woman (age
Panic disorder
Gentile (2008) Case report Italy 1 pregnant woman (age
Nascimento et al. (2004) Case reports Brasil 2 pregnant women (age
Robinson et al. (1992) Case series 3 pregnant woman (ageZ
Uguz et al. (2013) Case report Turkey 1 pregnant woman (age
Uguz et al. (2014) Case series Turkey 16 pregnant women (age
Ware and DeVane (1990) Case reports USA 2 pregnant women (ageZ
Speciﬁc phobia
Lilliecreutz et al. (2010) Open trial Sweden 30 pregnant women (me
Postpartum
Obsessive–compulsive disorder
Arnold (1999) Open-label
trial
USA 3 women (mean age 31.7
Challacombe and Salkovskis
(2011)
Case series UK 6 women (age range 25–
Christian and Storch (2009) Case report 1 women (age 26)
Hertzberg et al. (1997) Case report USA 1 women (age 25)
Hudak and Wisner (2012) Case report USA 1 PPOCD woman (age 32
Misri and Milis (2004) Open-label
trial
Canada 14 treatment-resistant O
(32.974.11)
Sichel et al. (1993) Case series USA 15 women (ageZ18)
Uguz et al. (2008) Case series Turkey 2 treated PPOCD women
25.1875.40)
Wisner et al. (1995) Case series USA 4 clomipramine-treated b
Z18)
OCD: obsessive–compulsive disorder; PPOCD: postpartum-onset obsessive–compulsive
Manual of Mental Disorders, Fourth Edition; Y-BOCS: Yale–Brown Obsessive–Compulsiv
Inventory–Revised; IPSA: Injection Phobia Scale-Anxiety; IPSAV: Injection Phobia Scal
ventory; CGI: Clinical Global Impressions Scale; CGI-I: Clinical Global Impression-Impro
Statistical Manual of Mental Disorders.
* Checklist for measuring study quality developed by Downs and Black.relevant articles. After removing duplicates, 756 articles were re-
trieved. Studies were screened and selected on the basis of pre-
speciﬁed inclusion and exclusion criteria (Fig. 1). The search
identiﬁed 18 articles that were included in the systematic review.
Fifteen of the 18 studies (83%) were case reports/case series,
and three (17%) open label trials. The study population was more
than 25 subjects in only 11% (n¼2) of the included studies. The
majority of the studies were conducted in North America (n¼7,
39%) and only 3 studies (17%) were conducted in Europe. In all the
considered studies diagnosis of anxiety disorders were based on
the DSM (Diagnostic and Statistical Manual of Mental Disorders)
criteria and were established using validated assessment scales
(Table 1).
No study on the treatment of generalised anxiety disorder
(GAD), social phobia, post-traumatic stress disorder, and other
anxiety disorders in perinatal period fulﬁlled our inclusion criteria.
3.1. Treatment of anxiety disorders during pregnancy
3.1.1. Non-pharmacological treatment
3.1.1.1. Obsessive–compulsive disorder. One case report supported
the use of cognitive-behavioural therapy (CBT) for obsessive–
compulsive disorder (OCD) during pregnancy (Chelmow and
Halﬁn, 1997) (Table 2). The patient was successfully managed with
CBT (“thought-stopping” technique) in combination with frequent
visits (every 1–2 weeks) to both her obstetrician and a psychiatrist
with special interest in psychiatric disorders in the perinatal
period.Sample size Diagnosis assessment Quality*
28) 1 DSM-III-R 18/31
30) 1 DSM 18/31
27) 1 DSM-IV-TR 18/31
29) 2 DSM-IV 19/31
18) 3 DSM 20/31
26) 1 SCID-I, CGI-I; HAM-D; DSM-
IV
18/31
range 19–37) 16 SCID-I, CGI; DSM-IV 19/31
18) 2 DSM 18/31
an age 28.575.03) 30 IPSA; IPSAV; EPDS; BAI;
DSM-IV
24/31
76.9) 3 SCID-I, Y-BOCS; DSM-IV 22/31
44) 6 SCID-I, Y-BOCS; DSM-IV 19/31
1 ADIS, Y-BOCS, OCI-R; DSM-
IV
18/31
1 DSM 18/31
) 1 DSM-IV-TR 18/31
CD women mean age 14 Y-BOCS, CGI; DSM-IV 23/31
15 DSM-III-R 19/31
þ 9 controls (mean age 2 SCID-I, Y-BOCS; DSM-IV 19/31
reastfeeding women (age 4 DSM 19/31
disorder; SCID-I: Structured Clinical Interview for the Diagnostic and Statistical
e Scale; ADIS: Anxiety Disorders Interview Schedule; OCI-R: Obsessive Compulsive
e-Avoidance; EPDS: Edinburgh Postnatal Depression Scale; BAI: Beck Anxiety In-
vement Scale; HAM-D: Hamilton Rating Scale for Depression; DSM: Diagnostic and
* Search strategy limited to January 2015, English language and human subjects older than 13 years old.
Fig. 1. Flow diagram of papers selected.
C. Marchesi et al. / Journal of Affective Disorders 190 (2016) 543–5505463.1.1.2. Panic disorder. One study in the literature supports the use
of CBT for panic disorder (PD) during pregnancy and lactation,
with good control of anxiety symptoms and clinical remission of
PD (Robinson et al., 1992) (Table 2).
3.1.1.3. Speciﬁc phobia. An open trial with two group CBT sessions
for blood- and injection phobia was conducted on 30 pregnant
women that were clinically assessed before and after each group
therapy session, as well as three months after delivery (Table 2).
The scores on the “Injection Phobia Scale-Anxiety” decreased after
each treatment session, and remained stable up to at least
3 months postpartum. CBT seemed also to reduce anxiety and
depressive symptoms during pregnancy (Lilliecreutz et al., 2010).
3.1.2. Pharmacological treatment
3.1.2.1. Obsessive–compulsive disorder. One case report supported
the use of ﬂuoxetine for OCD during pregnancy (Table 2). Con-
taminating obsessions and washing compulsions started at the
beginning of the pregnancy and the patient took ﬂuoxetine (up to
60 mg/day) until the last month of gestation with no side effects
for the baby (e.g. birth weight, gestational age, Apgar scores, cy-
anosis, respiratory distress, and tachypnea). Complete remission of
obsessive–compulsive symptoms was reported in the following
year (Kalra et al., 2005).3.1.2.2. Panic disorder. With regard to selective serotonin reuptake
inhibitors (SSRIs), few case reports support the use of citalopram
(Uguz, 2013) and escitalopram (Gentile, 2008) for PD during
pregnancy (Table 2). Two pregnant women with PD, who under-
went citalopram (20 mg/day) and escitalopram (40 mg/day)
treatments, respectively, presented good control of anxiety
symptoms and healthy outcomes for the child. Furthermore,
adding mirtazapine to the SSRIs treatment, the patient reported a
dramatic decrease in nausea, insomnia and appetite loss without
any neonatal complication in the baby (Uguz, 2013).
With regard to tricyclic antidepressants (TCAs), PD patients treated
with nortryptiline (Nascimento et al., 2004) and imipramine (Uguz
et al., 2014; Ware and DeVane, 1990) beneﬁted from pharmacother-
apy, reporting remission of panic symptoms. In the largest clinical
sample to date, based on the Clinical Global Impression-Improvement
Scale (CGI-I), 75% of pregnant women responded to low doses of
imipramine (10–40mg/day) with a statistically signiﬁcant reduction of
the mean number of panic attacks per week from 12.9 to 2.7 before
and after the treatment, respectively (Uguz et al., 2014) (Table 2).
3.2. Treatment of anxiety disorders during postpartum
3.2.1. Non-pharmacological treatment
3.2.1.1. Obsessive–compulsive disorder. Two case reports supported
the use of CBT, alone or in combination of pharmacotherapy (SSRIs),
Table 2
Intervention and results of selected studies.
References Intervention Results
Pregnancy
Obsessive–compulsive disorder
Chelmow and Halﬁn (1997) CBT sessions (“thought-stopping” technique) OCD successfully managed with CBT in combination with frequent visits (every
1–2 weeks) to both her obstetrician and her psychiatrist.
Kalra et al. (2005) Fluoxetine (up to 60 mg/day), 3rd–8th month of
gestation
Healthy infant. No OCS at one-year follow up.
Panic disorder
Gentile (2008) Escitalopram (40 mg/day) and alprazolam (1.5 mg/day) Decrease in panic symptoms; healthy infant.
Nascimento et al. (2004) Nortryptiline (75 mg/day and 100 mg/day,
respectively)
Complete remission of panic symptoms
Robinson et al. (1992) CBT sessions Decrease in panic symptoms.
Uguz et al. (2013) Citalopram (20 mg/day) and mirtazapine (7.5 mg/day) Decrease in nausea, insomnia and appetite loss; good control of panic symptoms;
healthy infant.
Uguz et al. (2014) Imipramine (10–40 mg/day) Decrease in the mean number of panic attacks per week before and after the
treatment.
Ware and DeVane (1990) Imipramine low doses Decrease in panic symptoms.
Speciﬁc phobia
Lilliecreutz et al. (2010) 2 CBT session group Decrease in the scores of the IPSA during pregnancy and postpartum (up to at
least 3 months); good control of anxiety and depressive symptoms.
Postpartum
Obsessive–compulsive disorder
Arnold (1999) Fluvoxamine (up to 300 mg/day) 2 of the 3 patients experienced a positive response (↓Z30% in the Y-BOCS total
score).
Challacombe and Salkovskis
(2011)
CBT sessions (12 h/2 weeks; up to 3 follow-up sessions
offered at monthly intervals)
Clinical beneﬁts reported in terms of own symptoms and in parenting in general.
Christian and Storch (2009) CBT sessions Clinical remission of OCD
Hertzberg et al. (1997) Clomipramine (100 mg/day) Decrease in OCS
Hudak and Wisner (2012) Citalopram (80 mg/day); psychoeducation sessions;
exposure with response prevention therapy
Decrease in OCS
Misri and Milis (2004) Quetiapine augmentation of SSRIs or SNRIs Decrease in OCS in 11 treatment-resistant OCD women (reduction of 59.6% in the
Y-BOCS score). Sedation was the most commonly reported side effect.
Sichel et al. (1993) Fluoxetine, cloipramine, desipramine (or a combina-
tion of this drugs)
Decrease in OCS in all 15 patients. At 1-year follow-up, 12 patients had elected to
remain on pharmacotherapy because of the presence of residual obsessions.
Uguz et al. (2008) Sertraline (150 mg/day) Clinical remission of OCD and decrease in OCS in the 2 patients treated with
sertraline, respectively.
Wisner et al. (1995) Clomipramine (75–125 mg/day) No adverse clinical effects were observed in the infants; good control of OCS
OCD: obsessive–compulsive disorder; OCS: obsessive–compulsive symptoms; CBT: cognitive behaviour therapy; m-ECT: modiﬁed-electroconvulsive therapy; IPSA: Injection
Phobia Scale-Anxiety; Y-BOCS: Yale–Brown Obsessive–Compulsive Scale; SSRIs: selective serotonin reuptake inhibitors; SNRIs: Serotonin–norepinephrine reuptake in-
hibitors; AD: antidepressant; Differences statistically signiﬁcant (po0.05).
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toms and parenting in general (Challacombe and Salkovskis, 2011;
Christian and Storch, 2009) (Table 2). In particular, for one woman,
eight sessions of CBT induced the clinical remission of postpartum
OCD (Christian and Storch, 2009).
3.2.2. Pharmacological treatment
3.2.2.1. Obsessive–compulsive disorder. Studies included in the re-
view supported the use of SSRIs (citalopram, sertraline, ﬂuoxetine,
ﬂuvoxamine) (Arnold, 1999; Hudak and Wisner, 2012; Sichel et al.,
1993; Uguz et al., 2008) and TCAs (clomipramine, desipramine)
(Sichel et al., 1993; Wisner et al., 1995; Hertzberg et al., 1997) with
statistically signiﬁcant symptom improvement (Table 2). In parti-
cular, in the largest clinical sample to date, 65% of the patients who
entered the open-label trial of ﬂuvoxamine (up to 300 mg/day)
experienced a 30% or greater decrease in the total score on the
Yale–Brown Obsessive–Compulsive Scale (Y-BOCS) (Arnold, 1999).
With regard to alternative therapeutic approaches, Misri and
colleagues conducted an open-label trial to investigate the efﬁcacy
of twelve-week quetiapine augmentation of SSRIs or serotonin–
norepinephrine reuptake inhibitors (SNRIs) in resistant OCD in the
postpartum period (Misri and Milis, 2004). They reported a sta-
tistically signiﬁcant reduction in obsessive–compulsive symptoms
between baseline and end point (Table 2).
4. Discussion
Studies included in this review supported the use of CBT forOCD, PD and speciﬁc phobia both in pregnancy and postpartum.
SSRIs led to signiﬁcant OCD and PD improvement both in preg-
nancy and postpartum with no side effects for the babies. In the
largest clinical sample to date, 65% of postpartum patients who
entered the open-label trial of ﬂuvoxamine (up to 300 mg/day)
experienced a 30% or greater decrease in the total score of the
Y-BOCS. During pregnancy, SSRIs and TCAs led to remission of
panic symptoms and healthy outcomes for the babies.
During pregnancy, guidelines for the treatment of OCD, PD,
GAD, agoraphobia, and social phobia suggest the consideration of
psychosocial and psychotherapeutic interventions, particularly
CBT, in lieu of pharmacotherapy (American Psychiatric Association,
2007, 2009). Pharmacotherapy may be indicated for pregnant
women with refractory anxiety disorders.
As conﬁrmed by this review, scant and heterogeneous data are
available on treatment strategies of AnxD in perinatal period, but,
given the current guideline recommendations and available sci-
entiﬁc evidence, some observations can be made.
4.1. Clinical practice suggestions for the treatment of pregnant
women
Psychotherapy, particularly CBT, should be the ﬁrst line treat-
ment of AnxD in pregnant women due to its efﬁcacy and safety.
Limitations for the use of CBT are the availability of experienced
therapists, the severity of the disorder and the need to perform
“homework” or to confront feared situations.
Although, according to the guidelines, pharmacotherapy may
C. Marchesi et al. / Journal of Affective Disorders 190 (2016) 543–550548be indicated in pregnant women with refractory AnxD, in the last
decade, the use of a SSRI compound in pregnancy is widespread in
clinical practice. In fact, as demonstrated by data collected by the
Swedish and Danish Medical Birth Registers, and by The USA
Medicaid database (Reis and Kallen, 2010; Huybrechts et al., 2014;
Jimenez-Solem et al., 2013), nearly all the available SSRI com-
pounds are largely prescribed in pregnant women (14,979 women
in Sweden, 35,414 in Denmark and 46,144 in USA), even within the
ﬁrst trimester of pregnancy (5123 women in Sweden, 15,403 in
Denmark and 46,144 in USA), at a time when the drugs may exert
their possibly teratogenic effect.
In these populations, which did not involve only depressed
women, the risk of any major malformation (a malformation that
severely impaired function or that needed a surgical correction of
the affected organ) and particularly of any cardiac malformation
did not increase in women treated with SSRIs (OR 0.87; CI 95%
0.76–1.01 and 1.06; CI 95% 0.93–1.22, respectively) (Reis and Kal-
len, 2010; Huybrechts et al., 2014). Similarly, no substantial in-
crease was found in the overall prevalence of cardiac birth defects
among infants exposed to SSRIs or venlafaxine in a large cohort
study (Furu et al., 2015) and a recent bayesian analysis of previous
reports found an increased risk of birth defects only for paroxetine
or ﬂuoxetine early in pregnancy.
Nevertheless, in Swedish Register (Reis and Kallen, 2010) an
increased risk of cardiac defects (mainly atrial or ventricular sep-
tum defects) (OR¼1.66; CI 95% 1.09–2.53) was observed in infants
of women exposed to paroxetine (but not to other SSRI com-
pounds) during the ﬁrst trimester of pregnancy. This ﬁnding was
not conﬁrmed (OR¼0.94; CI 95% 0.73–1.21) in a recent study in-
volving 11,126 women who were treated with paroxetine in the
ﬁrst trimester (Huybrechts et al., 2014). Finally, the risk of cardiac
and other malformations did not increase with the use of high
doses of SSRIs (Jimenez-Solem et al., 2013).
A recent meta-analysis suggests that SSRIs exposure during
pregnancy increased the risk of low birth weight (o2500 gr)
(RR¼1.48; 95%CI 1.22–1.79) and preterm birth (o37 weeks ge-
station) (RR¼1.74; 95% CI 1.52–2.00). These effects were more
pronounced in depressed women than in anxious women (Huang
et al., 2014). These ﬁndings conﬁrm the data of a previous meta-
analysis, which found an increased risk for low birth weight
(RR¼1.49; 95% CI, 1.25–1.77) and for preterm birth (RR¼1.39; 95%
CI, 1.19–1.61) in the new-borns of mothers with untreated de-
pressive disorders during pregnancy (Grote et al., 2010). Finally, a
case-control study, involving women with depressive or anxiety
disorders, found an increased risk for preterm birth (OR¼5.07, 95%
CI¼1.34–19.23), but not for low birth weight, in new-borns ex-
posed to high doses of SSRIs (Roca et al., 2011).
In late pregnancy, the administration of SSRIs exposes the new-
borns to the following two risks:
1. increased risk of poor neonatal adaptation syndrome (OR 5.07;
CI 95% 3.25–7.90). This affects up to 30% of new-borns and is
generally transient, being only very occasionally severe enough
to require treatment (Grigoriadis et al., 2013). This risk is
prevented if the mother maintained the SSRIs after delivery
(see breastfeeding);
2. increased risk of persistent pulmonary hypertension (OR 2.5; CI
95% 1.32–4.73) (Grigoriadis et al., 2014). Although statistically
signiﬁcant, clinically, the absolute risk of persistent pulmonary
hypertension in the new-born remained low, as 2.9–3.5 per
1000 infants exposed to SSRIs in late pregnancy developed this
condition (Grigoriadis et al., 2014). As such, the Food and Drug
Administration “ does not ﬁnd sufﬁcient evidence to conclude
that SSRIs use in pregnancy causes persistent pulmonary
hypertension in the new-born” (Drug Safety Communication,
12.14.2011).Concerning the cognitive, psychomotor and behavioural effects
of the in-utero exposure to SSRIs on new-borns, a recent study
demonstrated in depressed mothers no impact on cognitive and
behavioural development, while a minimal effect (within the
normal range) was found on psychomotor functioning in the ﬁrst
year (Santucci et al., 2014). A recent review found that in-utero
exposure to SSRIs has an effect on later cognitive and behavioural
development but no effect on early development (Hermansen and
Melinder, 2014). However, it remains to be determined whether
the effects on child development found after SSRIs treatment in
pregnant women are only due to the SSRIs exposure or if the
underlying depression is also involved (Olivier et al., 2014).
The use of benzodiazepines (BDZ) is not recommended during
pregnancy (Iqbal et al., 2002), particularly in the ﬁrst trimester due
to the risk of cleft lip/palate, even though the absolute risk is low
(Bellantuono et al., 2013), and in late pregnancy for the occurrence
of a withdrawal syndrome or a “ﬂoppy baby syndrome” in BDZ
dependent new-borns.
In conclusion, concerning the pharmacological treatment of
pregnant women, the safety proﬁle of the SSRIs used during
pregnancy, even in the ﬁrst trimester, based on the ﬁndings of the
recent large meta-analyses, is reassuring. However, we suggest
prescribing sertraline and citalopram particularly, which are the
safer and better studied SSRIs for use during pregnancy.
4.2. Clinical practice suggestions for the treatment of breastfeeding
women
Some authors suggested that in the postpartum, there is no
reason that the treatment of AnxD should differ from AnxD out-
side the perinatal period (Abramowitz et al., 2003). This sugges-
tion is safely applicable for both psychotherapy, which should be
the ﬁrst line treatment of AnxD in breastfeeding women, and also
for pharmacotherapy. In fact, the available data concerning the
effects of exposure of breastfeeding infants to a SSRI drug are re-
assuring, and breastfeeding should not be generally discouraged in
women using SSRIs.
A recent review (Rowe et al., 2015) demonstrated that in
breastfeeding mothers the transfer of sertraline, ﬂuvoxamine, and
paroxetine into human milk is low and uptake by the infant is
even lower. Thus far, no or minimal untoward effects have been
reported following the use of these three compounds in breast-
feeding mothers. Sertraline is overwhelmingly favoured, as more
than 50 mother–infant pairs have been evaluated, and milk and
infant plasma levels are low to undetectable. In breastfeeding,
ﬂuoxetine and citalopram should not be the drugs of ﬁrst choice,
because the long plasma half-life of the former and the detectable
plasma level in new-borns for the latter may cause adverse effects
in infants (Rowe et al., 2015).
Concerning BDZ, in a prospective study only 2 (1.6%) infants (2–
24 months old) of 124 women taking BDZ (52% lorazepam, 18%
clonazepam and 15% midazolam) were found to have central
nervous system depression (Kelly et al., 2012). If these agents are
used, choose a product with a short half-life and use the lowest
effective dose for the shortest duration to minimise exposure.5. Limitations
The main limitation of included studies is sample size, as
documented by the quality assessment scores. Only four studies
(22%) were assigned a score equal or greater than 20/31 on the
Downs and Black quality scale (Downs and Black, 1998) (Table 1).
The majority of the selected studies are case reports (83%, 15/18)
with only three clinical trials (17%). Study design and enrolment of
subjects mainly from outpatient specialty units might have limited
C. Marchesi et al. / Journal of Affective Disorders 190 (2016) 543–550 549community-wide generalisability.
Another limitation is the inclusion of papers published only in
English. The the four papers included in the Other Sources section,
were retrieved from the grey literature (i.e. through the internet
and among the references of the potentially relevant studies),
nonetheless this search has not been systematic and could results
in a further bias of a review (Mahood et al., 2014). Considering the
limited number of studies; the broad scope of diagnosis; types of
treatment included and the diversity of study designs (including
both case studies and clinical trials), the conclusions extracted
cannot be easily generalised.
The main strength of this study is that it is the ﬁrst systematic
review of this topic, and thus includes the entire available body of
scientiﬁc evidence. Further, in all included original studies the
diagnosis of AnxD were consistently based on the DSM criteria and
were established by trained investigators using validated assess-
ment scales mainly with interrater reliability.Competing interests
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